Ways of Regulating Drugs in the 19th and 20th Centuries

Front Matter....Pages i-xiv
General Introduction....Pages 1-16
Secrets, Bureaucracy, and the Public: Drug Regulation in Early 19th-Century Prussia....Pages 17-42
Making Salvarsan: Experimental Therapy and the Development and Marketing of Salvarsan at the Crossroads of Science, Clinical Medicine, Industry, and Public Health....Pages 43-65
Professional and Industrial Drug Regulation in France and Germany: The Trajectories of Plant Extracts....Pages 66-96
Making Risks Visible: The Science, Politics, and Regulation of Adverse Drug Reactions....Pages 97-120
Regulating Drugs, Regulating Diseases: Consumerism and the US Tolbutamide Controversy....Pages 121-150
Thalidomide, Drug Safety Regulation, and the British Pharmaceutical Industry: The Case of Imperial Chemical Industries....Pages 151-180
What’s in a Pill? On the Informational Enrichment of Anti-Cancer Drugs....Pages 181-205
Treating Health Risks or Putting Healthy Women at Risk: Controversies around Chemoprevention of Breast Cancer....Pages 206-227
AZT and Drug Regulatory Reform in the Late 20th-Century US....Pages 228-244
Professional, Industrial, and Juridical Regulation of Drugs: The 1953 Stalinon Case and Pharmaceutical Reform in Postwar France....Pages 245-269
Managing Double Binds in the Pharmaceutical Prescription Market: The Case of Halcion....Pages 270-286
Pharmaceutical Patent Law In-the-Making: Opposition and Legal Action by States, Citizens, and Generics Laboratories in Brazil and India....Pages 287-317
Back Matter....Pages 319-327